Cantargia highlights AACR preclinical data for nadunolimab plus ras inhibition in PDAC
Cantargia said preclinical data presented at AACR supports nadunolimab combined with ras inhibition in PDAC, citing two approaches acting on non-overlapping parts of PDAC biology and impacts on the tumor microenvironment and tumor burden.
Sept. 30 (Reuters) — Cantargia AB said preclinical data presented at AACR support nadunolimab in combination with RAS inhibition in PDAC. The company said the two approaches act on non-overlapping parts of PDAC biology, with the combination reshaping the tumor microenvironment and reducing tumor burden. com; +48 58 772 0920;)